CARACAS: President Nicolas Maduro said that Venezuela would produce 2 million doses per month of Cuban coronavirus vaccine.
Maduro added that the South American country would join Venezuela in Phase 3 trials for the Abdala vaccine produced by its socialist ally.
Nicolas Maduro announced on the television address that they are signing an agreement to produce in their laboratories, minimum of two million vaccines a month of the Abdala vaccine for august September approximately.
In the last week, the government declared that it’s possible to produce 30 million doses of vaccines, but it needs only for the economic sanctions that the United States leads.
Juan Guaido, the opposition leader, delivered a statement against Nicolas Maduro by ensuring that the government is lying about vaccines’ production. He also claimed that Maduro is the reason behind Venezuela’s lack of COVID -19 vaccines because vaccines developed by Cuba are in various stages of trials.
The Cuba have already started vaccinating their health care workers with its two vaccines still in the third phase of clinical trials.
One vaccine named Abdala is being given to 1,24,000 health workers, while 48,000 volunteers joined in a parallel Phase 3 clinical trial.
Now the question is, should it be approved that Abdala would be the first COVID-19 vaccine entirely developed and produced in Latin America.
are progressing slowly because the country receives just 2,50,000 Russian Sputnik V vaccine doses and half a million from China’s Sinopharm to date.
Maduro also declared that his government would also sign deals to produce manufacture Russian and Chinese COVID-19 vaccines.
The Venezuelan government informed that it had paid just over half of the amount; it needs to acquire 11.3 million doses through the World Health Organization’s Covax mechanism.
Finally, it is approved by the authorities that the country of 30 million has had 1,75,000 cases and 17,000 deaths. But the experts observed, such as Human Rights Watch, questioned the numbers, which they say are likely vastly underestimated.